- Recommendation ID
- For people with CKD at the highest risk of cardiovascular disease, what is the clinical effectiveness of low-dose aspirin compared with placebo for primary prevention of cardiovascular disease?
- Any explanatory notes
- Why this is important: CKD is a common long-term condition and a powerful independent predictor of cardiovascular disease. The risks are increased as the estimated glomerular filtration rate (eGFR) decreases and level of albuminuria increases. Kidney Disease: Improving Global Outcomes (KDIGO) classifies people with CKD as being at moderate risk, high risk or very high risk of cardiovascular disease according to their eGFR and albumin:creatinine ratio (ACR). However, the current evidence base for reducing cardiovascular risk in the CKD population is very limited.
Source guidance details
- Comes from guidance
- Chronic kidney disease in adults: assessment and management
- Date issued
- July 2014
|Is this a recommendation for the use of a technology only in the context of research?||No|
|Is it a recommendation that suggests collection of data or the establishment of a register?||No|